Sparks commentary - IRLAB Therapeutics

Healthcare

Sparks - IRLAB Therapeutics

More on this equity
IRLAB Therapeutics_resized
IRLAB (OMX: IRLAB-A) – last patient completes treatment in pirepemat trial
Published by Arron Aatkar, PhD

IRLAB has announced that all patients enrolled in the REACT-PD trial have completed treatment and had their final follow-up visit. This Phase IIb study is evaluating IRLAB’s prefrontal cortex enhancer, pirepemat, as a potential therapy to improve balance and reduce falls in Parkinson’s disease patients. Top-line results are due to be reported in Q125, consistent with prior guided timelines for the trial.

Latest

Industrials | Comment

Earnz (AIM: EARN) – Proposed acquisition of Zero Carbon Group

Industrials | Comment

Electro Optic Systems (ASX: EOS) announces US$45m order win

Financials | Comment

Revolut secures full UK banking licence

Healthcare | Comment

OSE Immunotherapeutics (PAR: OSE) confirms new CEO